What is Cellectar Biosciences?
Cellectar Biosciences operates at the intersection of advanced oncology research and precision medicine. The company is primarily focused on the discovery, development, and commercialization of targeted therapies for cancer treatment. Its core asset, CLR 131 (iopofosine I-131), represents a significant innovation in the delivery of therapeutic radiation directly to malignant cells. With ongoing Phase 2 clinical studies targeting B-cell malignancies, Waldenstrom's macroglobulinemia, and multiple myeloma, the company has established a critical market position as a developer of next-generation radiotherapeutics. By addressing high-unmet-need patient populations, including pediatric cases and refractory solid tumors, Cellectar differentiates itself through a highly specialized, science-led approach to therapeutic intervention.
How much funding has Cellectar Biosciences raised?
Cellectar Biosciences has raised a total of $234.6M across 14 funding rounds:
Stock Offering
$9.2M
Stock Offering
$7.8M
Stock Offering
$16.6M
Stock Offering
$10M
Debt
$150K
Share Placement
$102.9M
Stock/Share Issuance
$2.5M
Stock Issuance/Offering (2016): $9.2M supported by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2017): $7.8M featuring Undisclosed
Stock Issuance/Offering (2018): $16.6M backed by Ladenburg Thalmann & Co.
Stock Issuance/Offering (2019): $10M with participation from Roth Capital Partners
Debt (2020): $150K led by PPP
Share Placement (2023): $102.9M supported by Second Line and Rosalind Advisors
Stock/Share Issuance (2025): $2.5M, investors not publicly disclosed
Key Investors in Cellectar Biosciences
OrbiMed
OrbiMed is a premier healthcare-focused investment firm that manages capital across the biopharmaceutical and medical device sectors, leveraging deep industry expertise to support innovation from early-stage ventures to established organizations.
National Cancer Institute
The NCI is a federal agency dedicated to reducing the cancer burden through rigorous research, the development of novel therapeutic interventions, and the support of clinical trials.
Rosalind Advisors
Rosalind Advisors is a specialized investment firm focused on the life sciences sector, managing biotech-specific funds to capitalize on advancements in medical research and drug development.
What's next for Cellectar Biosciences?
With the recent capital injection, Cellectar Biosciences is poised to accelerate its clinical development milestones. The strategic focus will likely remain on the advancement of its lead PDC candidates through late-stage clinical trials, with an emphasis on data readout and regulatory engagement. As the company transitions from a research-heavy entity to a potential commercial-stage organization, management will likely prioritize operational efficiency and the scaling of manufacturing capabilities to support future market entry. The continued support from specialized life science investors suggests a long-term commitment to validating the PDC platform's efficacy across a broader spectrum of oncological indications, potentially opening doors for future strategic partnerships or licensing agreements.
See full Cellectar Biosciences company page
